Salomon Manier, MD, PhD, Sees Promising Therapy Data in Elderly Patients With Myeloma
By Salomon Manier, MD, PhD, Andrew Moreno - Last Updated: July 17, 2024Salomon Manier, MD, PhD, Associate Professor of Hematology at Lille University Hospital in France, tells Blood Cancers Today which of the newly presented phase III data on myeloma care he found most exciting at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.
Advertisement
Post Tags:EHA 2024
Advertisement
Related Posts
The agent is designed to be an option for cases where CAR T-cell therapies or first-generation bispecifics are unsuccessful.
In the US, a BLA submitted for these two particular combinations is currently under review at the FDA.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.